{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:32:36Z","timestamp":1790623956855,"version":"4.1.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffman-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0157957","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T19:37:44Z","timestamp":1467315464000},"page":"e0157957","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":99,"title":["Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries"],"prefix":"10.1371","volume":"11","author":[{"given":"Erwin","family":"De Cock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Persefoni","family":"Kritikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunning","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ngoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Waterboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"J Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref2","year":"2015","unstructured":"SEER (Surveillance, Epidemiology and End Results Program): Stat Fact Sheets: Non-Hodgkin Lymphoma. <year>2015<\/year>. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html\" xlink:type=\"simple\">http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html<\/ext-link>."},{"issue":"Suppl.","key":"ref3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0609.2006.00789.x","article-title":"The therapeutic use of rituximab in non-Hodgkin&apos;s lymphoma","volume":"67","author":"R Marcus","year":"2007","journal-title":"Eur J Haematol"},{"key":"ref4","article-title":"European Medicines Agency: MabThera","year":"2009"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1523-5394.1998.006003195.x","article-title":"Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin\u2019s lymphoma","volume":"6","author":"SD Scott","year":"1998","journal-title":"Cancer Pract"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/era.09.30","article-title":"Rituximab and chemotherapy in diffuse large B-cell lymphoma","volume":"9","author":"A Sonet","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003495-200767030-00002","article-title":"Monoclonal antibodies in the treatment of non-Hodgkin&apos;s lymphoma","volume":"67","author":"MA Fanale","year":"2007","journal-title":"Drugs"},{"key":"ref8","article-title":"Hoffmann-La Roche Ltd","author":"F. Data on File"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2858.2858","article-title":"A two-stage Phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with follicular lymphoma as part of maintenance treatment","volume":"116","author":"A Salar","year":"2010","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2013.52.2631","article-title":"A comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase Ib study","volume":"32","author":"A Salar","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"A Davies","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(14)70009-9","article-title":"Subcutaneous rituximab: a practical approach?","volume":"15","author":"K Tobinai","year":"2014","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cam4.573","article-title":"A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer","author":"E De Cock","year":"2016","journal-title":"Cancer Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3111\/13696998.2014.914033","article-title":"Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom","volume":"17","author":"S Rule","year":"2014","journal-title":"J Med Econ"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4236\/abcr.2013.24022","article-title":"Subcutaneous trastuzumab (Herceptin<sup>\u00ae<\/sup>): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER-2 positive early breast cancer","volume":"2","author":"R Burcombe","year":"2013","journal-title":"Adv Breast Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3052.3052","article-title":"A randomized comparison of maintenance therapy with subcutaneous rituximab for 2 years versus until progression in patients with indolent non-Hodgkin\u2019s lymphoma: interim safety data from the MABCUTE study","volume":"122","author":"S Rule","year":"2013","journal-title":"Blood"},{"key":"ref17","article-title":"Non-clinical pharmacokinetic\/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab","author":"B Bittner","journal-title":"Drug Res (Stuttg)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"X Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref19","article-title":"Patient preference for subcutaneous or intravenous administration of rituximab in previously untreated CD20+ non-Hodgkin lymphoma: interim data from the PrefMab study","volume":"99","author":"M Rummel","year":"2014","journal-title":"Haematologica (EHA annual congress abstracts)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","article-title":"Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects","volume":"67","author":"J McCambridge","year":"2014","journal-title":"J Clin Epidemiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0157957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T04:54:39Z","timestamp":1600836879000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0157957"}},"subtitle":[],"editor":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0157957","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}